about
Prognostic and Therapeutic Markers in Chordomas: A Study of 287 Tumors.Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapyBifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.The autophagy GABARAPL1 gene is epigenetically regulated in breast cancer modelsPrognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer.Human papillomaviruses in colorectal cancers: A case-control study in western patients.The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status.Pediatric Chordomas: Results of a Multicentric Study of 40 Children and Proposal for a Histopathological Prognostic Grading System and New Therapeutic Strategies.Somatic mutational spectrum analysis in a prospective series of 104 gastrointestinal stromal tumors.Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: a comprehensive immunophenotypical and molecular analysis.A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine.Prognostic value of phosphorylated STAT3 in advanced rectal cancer: a study from 104 French patients included in the EORTC 22921 trial.[Authorization of pathologists for the estimation of the tumor cell percentage on tissue sample for molecular analysis purpose]
P50
Q33275854-F0C46553-8B76-45A1-AFCE-41195EB3A2AFQ33417019-E3BDDB06-212E-44A7-A4AF-2C877EC357F2Q35076861-36B9FE1A-46F6-4B65-98A1-3C3313286EF8Q35810837-651EC646-C395-45A3-9B69-A613FCB42CB5Q36724011-08E11A16-16AA-4F5B-9CBA-0F36F4744A9FQ38723482-E35766B5-C807-45C0-8557-C5F7C3336E88Q39855050-766E2619-1D53-48F4-BAD4-7419CC862629Q40417709-C1372785-CCA6-41D1-8EC6-1F812CEBE13FQ43614338-25D4639C-7923-4FAB-AE92-4FF31F9299F1Q47557493-142F5613-DBC2-4AC1-9AB7-06EC6318DFBBQ47583602-1437E6A7-09EA-427E-BE5D-2767460B75B8Q48186799-BFD64C98-A8D5-4780-93F4-EFBFA5C5CE2AQ52560123-3D9A1D60-1DCF-45DB-BE37-BD90397AB97BQ53294933-E65C18E0-38B5-494A-AE01-9FEF16E6B9ABQ88027062-D3FEAE9C-38A3-4DAE-9694-B275A0461AC1
P50
description
researcher ORCID ID = 0000-0002-2799-3730
@en
wetenschapper
@nl
name
Franck Monnien
@ast
Franck Monnien
@en
Franck Monnien
@es
Franck Monnien
@nl
type
label
Franck Monnien
@ast
Franck Monnien
@en
Franck Monnien
@es
Franck Monnien
@nl
prefLabel
Franck Monnien
@ast
Franck Monnien
@en
Franck Monnien
@es
Franck Monnien
@nl
P106
P31
P496
0000-0002-2799-3730